HomeCompareCRAWA vs MRK

CRAWA vs MRK: Dividend Comparison 2026

CRAWA yields 2.43% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $34.4K in total portfolio value
10 years
CRAWA
CRAWA
● Live price
2.43%
Share price
$82.43
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.3K
Annual income
$283.77
Full CRAWA calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — CRAWA vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRAWAMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRAWA + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRAWA pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRAWA
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$241.20/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $8,355.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRAWA + MRK for your $10,000?

CRAWA: 50%MRK: 50%
100% MRK50/50100% CRAWA
Portfolio after 10yr
$40.5K
Annual income
$5,198.78/yr
Blended yield
12.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CRAWA
No analyst data
Altman Z
5.8
Piotroski
6/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRAWA buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRAWAMRK
Forward yield2.43%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$23.3K$57.7K
Annual income after 10y$283.77$10,113.78
Total dividends collected$2.6K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CRAWA vs MRK ($10,000, DRIP)

YearCRAWA PortfolioCRAWA Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,943$242.62$11,213$373.04$270.00MRK
2$11,957$248.13$12,667$512.06$710.00MRK
3$13,047$253.38$14,439$708.14$1.4KMRK
4$14,219$258.40$16,640$988.16$2.4KMRK
5$15,477$263.19$19,432$1,394.07$4.0KMRK
6$16,828$267.74$23,057$1,992.90$6.2KMRK
7$18,278$272.07$27,889$2,894.79$9.6KMRK
8$19,834$276.18$34,518$4,286.29$14.7KMRK
9$21,503$280.08$43,912$6,494.35$22.4KMRK
10$23,292$283.77$57,714$10,113.78$34.4KMRK

CRAWA vs MRK: Complete Analysis 2026

CRAWAStock

Crawford United Corporation, together with its subsidiaries, provides specialty industrial products and solutions in the United States, Puerto Rico, Mexico, Canada, and internationally. It operates through two segments, Commercial Air Handling Equipment, and Industrial and Transportation Products. The Commercial Air Handling segment designs, manufactures, and installs large-scale commercial, institutional, and industrial custom air handling solutions to health care, education, pharmaceutical, and industrial manufacturing markets under the FactoryBilt and SiteBilt brand names. The Industrial and Transportation Products segment is involved in the manufacture of flexible interlocking metal hoses primarily to heavy-duty truck manufacturers and aftermarket suppliers, as well as to the agricultural, industrial, and petrochemical markets; and distribution of silicone and hydraulic hoses to the agriculture and general industrial markets. The company also provides engineering, machining, grinding, welding, brazing, heat treat, and assembly solutions; rubber and plastic marine hose for the recreational boating industry; engineered manufacturing solutions, including CNC machining, anodizing, electro polishing, and laser marking for defense, aerospace, and medical device markets; and hydraulic hoses, air tank assemblies, and related products to manufacturers of firefighting trucks and other emergency vehicles. In addition, it engages in the supply of highly engineered forgings for the aerospace, industrial gas turbine, medical prosthetics, alternative energy, petrochemical, and defense industries; and developing and commercializing marketing and data analytic technology applications. The company was formerly known as Hickok Incorporated and changed its name to Crawford United Corporation in May 2019. Crawford United Corporation was founded in 1910 and is headquartered in Cleveland, Ohio.

Full CRAWA Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CRAWA vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRAWA vs SCHDCRAWA vs JEPICRAWA vs OCRAWA vs KOCRAWA vs MAINCRAWA vs JNJCRAWA vs ABBVCRAWA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.